Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Varex Imaging’s dual Medical and Industrial disclosures can feel like testing an x-ray tube under maximum load—dense specs, segment swaps, and regulatory cross-checks everywhere. That’s why this page doesn’t just list documents; it decodes them. Stock Titan’s AI digs into each filing so you can see, in plain English, where detector R&D is headed, how replacement-tube revenue trends, and when security-screening orders shift the Industrial backlog.
Need the Varex Imaging quarterly earnings report 10-Q filing or last quarter’s segment margins? One click delivers the PDF plus an AI summary of revenue drivers and cash-flow swings. Tracking executive incentives? Our dashboard flags Varex Imaging insider trading Form 4 transactions and streams Varex Imaging Form 4 insider transactions real-time, giving you context on board-level confidence. When a sudden contract win hits, the Varex Imaging 8-K material events explained card highlights what changed and why it matters.
Here’s how professionals use the page:
- Compare quarterly detector sales using Varex Imaging earnings report filing analysis.
- Spot option grants via Varex Imaging executive stock transactions Form 4.
- Review R&D spend in the Varex Imaging annual report 10-K simplified section.
- Examine leadership pay through the Varex Imaging proxy statement executive compensation viewer.
- Save hours by understanding Varex Imaging SEC documents with AI instead of manual searches.
All forms—10-K, 10-Q, 8-K, S-8, DEF 14A—arrive seconds after EDGAR posts, and our AI-powered summaries keep technical jargon from clouding critical insight. In short, this is Varex Imaging SEC filings explained simply, updated in real time and ready for decisive analysis.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting ownership of 1,992,611 shares of Varex Imaging Corp common stock, representing 4.8% of the outstanding class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership of the shares while acknowledging it may possess voting and/or investment power as adviser. Of the reported shares, 1,951,986 shares are listed as sole voting power and 1,992,611 as sole dispositive power. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.
Varex Imaging Corp (VREX) filed a Form 144 reporting a proposed sale of 3,174 common shares held by a person whose restricted stock vested on 05/15/2025. The shares are to be sold through Fidelity Brokerage Services LLC on or about 09/19/2025 on the NASDAQ, with an aggregate market value reported as $39,167.16. The filer indicates the shares were acquired as compensation upon vesting and reports no other sales in the past three months. The filing includes the standard Rule 144 representation that the seller is not aware of undisclosed material adverse information.
Jay K. Kunkel, a director of Varex Imaging Corp (VREX), sold 3,000 shares of the company's common stock on 08/14/2025 at $10.49 per share. After the sale, he beneficially owned 19,477 shares, reported as direct ownership. The Form 4 disclosure records the transaction and the sale price for each share.
The filing provides a straightforward record of insider liquidity: a director reduced his stake by 3,000 shares while maintaining a mid-sized direct holding in the company. No options, derivative transactions, or other compensatory arrangements are reported.
Varex Imaging Corporation (VREX) Form 144 filing: An insider proposes to sell 3,000 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $31,470. The shares represent restricted stock that vested and were acquired on 02/13/2023 as compensation. The sale is scheduled for approximately 08/14/2025 on NASDAQ. The filer reports 41,500,000 shares outstanding for this class. The filer also disclosed a prior sale of 2,575 shares on 06/18/2025 for gross proceeds of $20,007.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Pzena Investment Management LLC has filed Amendment No. 1 to Schedule 13G disclosing a passive ownership position in Varex Imaging Corporation (VREX).
- The value-oriented investment adviser now beneficially owns 4,244,977 common shares, representing 10.2 % of VREX’s outstanding stock.
- Sole voting power: 3,108,798 shares; sole dispositive power: the full 4,244,977 shares. No shares are held with shared voting or dispositive authority.
- The filing is made under Rule 13d-1(b) as an institutional investment adviser (IA), indicating the stake is held in the ordinary course of business and not for the purpose of influencing control.
- All shares are held on behalf of clients; no single client owns more than 5 % of the class.
- The filing date of the event is 30 June 2025; signature is dated 3 July 2025 by Chief Legal Risk & Compliance Officer Steven Coffey.
The >10 % threshold places Pzena among the largest institutional holders of VREX, potentially increasing trading liquidity and indicating external confidence in the company’s valuation, although the passive 13G designation suggests no activist intent.
Director Jay K. Kunkel of Varex Imaging Corp (VREX) reported a significant insider transaction on June 18, 2025. The filing discloses that Kunkel sold 2,575 shares of common stock at a price of $7.77 per share, resulting in a total transaction value of approximately $20,007.
Following this disposition, Kunkel's direct ownership position decreased to 22,477 shares of Varex Imaging common stock. The transaction was executed as a straight sale (Transaction Code: S) and was reported within the required filing deadline.
Key transaction details:
- Transaction Type: Direct sale of common stock
- Shares Sold: 2,575 at $7.77 each
- Remaining Direct Holdings: 22,477 shares
- Filing Status: Form 4 filed timely on June 20, 2025
FAQ
What is the current stock price of Varex Imaging (VREX)?
What is the market cap of Varex Imaging (VREX)?
